{"id":453759,"date":"2021-03-09T09:03:19","date_gmt":"2021-03-09T14:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453759"},"modified":"2021-03-09T09:03:19","modified_gmt":"2021-03-09T14:03:19","slug":"cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/","title":{"rendered":"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">AUSTIN, Texas, March  09, 2021  (GLOBE NEWSWIRE) &#8212; Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer\u2019s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer\u2019s disease.<\/p>\n<p align=\"justify\">\u201cI am pleased with our success to date in being an effective collaborator with Evonik, a company with a long, successful and reliable track record of supporting pharmaceutical supply chains,\u201d said Remi Barbier, President and CEO of Cassava Sciences.<\/p>\n<p align=\"justify\">\u201cWe are delighted to be collaborating with Cassava and contributing to fight Alzheimer\u2019s together. We are committed to supporting Cassava in their goals to maintain the quality of life for millions of patients around the world and to further advance potential treatment options,\u201d says Dr Thomas Riermeier, head of Evonik\u2019s Health Care business line. Evonik is one of the world\u2019s largest contract development and manufacturing organizations (CDMO) for active pharmaceutical ingredients and advanced intermediates.<\/p>\n<p align=\"justify\">\n        <strong>About Evonik <\/strong><br \/>\n        <br \/>Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of \u20ac12.2 billion and an operating profit (adjusted EBITDA) of \u20ac1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.<\/p>\n<p align=\"justify\">\n        <strong>About Cassava Sciences, Inc.<\/strong><br \/>\n        <br \/>Cassava Sciences\u2019 mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer\u2019s disease. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vzy3p00Jmaj5QBfmIq26ylooXcosPCOp_P91GnZZuTSMCZOcwC8XFX98-zGVrnOG_l8nCicTjceJIC4_fMuWX9lgG4xC7wZRBdQLh31TQ09KqcvgxyG8taIsUOlVn6Km-JI4XD4wuUp_QznfKEcDCTaC2DvjGxx0BMXncIbgaD0O2NgVjI6Dlonhui4zShkDTPkWOEAJI1RS-kSUFe0Zg_x2XN3rzUuGfuxeIiAaYtNX9fvjeZde1WIAQ01e_DuRONPH7wSFbnbuzR_S96D8lz1jsoSYo88DONY9SfZ1Xek=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.CassavaSciences.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>For More Information Contact:<\/strong><br \/>\n        <br \/>Eric Schoen, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FjeP53P2WbkuvyebT6cYcXs4PLdM0Le-gJqqPJyEFTTEk2e_FL0qxWR6NzsdIDcYrbzflrgUB9_gogqUvqXxHD_ACBBRXkWWzYXi19mCD9itAFl2jw_wEh9P2lBQKsm3\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">eschoen@CassavaSciences.com<\/a><br \/>(512) 501-2450\u00a0<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7efd72d3-b2ad-44ab-a24f-ee5acef683b0\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) &#8212; Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer\u2019s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer\u2019s disease. \u201cI am pleased with our success to date in being an effective collaborator with Evonik, a company with a long, successful and reliable track record of supporting pharmaceutical supply chains,\u201d said Remi Barbier, President and CEO of Cassava Sciences. \u201cWe are delighted to be collaborating with Cassava and contributing to fight Alzheimer\u2019s together. We are committed to supporting &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453759","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) &#8212; Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer\u2019s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer\u2019s disease. \u201cI am pleased with our success to date in being an effective collaborator with Evonik, a company with a long, successful and reliable track record of supporting pharmaceutical supply chains,\u201d said Remi Barbier, President and CEO of Cassava Sciences. \u201cWe are delighted to be collaborating with Cassava and contributing to fight Alzheimer\u2019s together. We are committed to supporting &hellip; Continue reading &quot;Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T14:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam\",\"datePublished\":\"2021-03-09T14:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/\"},\"wordCount\":316,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/\",\"name\":\"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI=\",\"datePublished\":\"2021-03-09T14:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/","og_locale":"en_US","og_type":"article","og_title":"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam - Market Newsdesk","og_description":"AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) &#8212; Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer\u2019s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer\u2019s disease. \u201cI am pleased with our success to date in being an effective collaborator with Evonik, a company with a long, successful and reliable track record of supporting pharmaceutical supply chains,\u201d said Remi Barbier, President and CEO of Cassava Sciences. \u201cWe are delighted to be collaborating with Cassava and contributing to fight Alzheimer\u2019s together. We are committed to supporting &hellip; Continue reading \"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T14:03:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam","datePublished":"2021-03-09T14:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/"},"wordCount":316,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/","name":"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI=","datePublished":"2021-03-09T14:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjI3NSM0MDUzNDg0IzIwMjc4MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453759"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453759\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}